Company · CIK 0000890821 · SIC 2834 — Pharmaceutical Preparations · Nasdaq
Enveric Biosciences, Inc. · ENVB
Insider activity reported against this company. All insider holders · On EDGAR ↗
Reported at this company — common stock
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 1, 2026 AForm 4 → | Jun 3, 4:34 pm EDT | Kevin Michael CoveneyChief Financial Officer | 133,333 | — | — | 180,746 | — | |
| Jun 1, 2026 AForm 4 → | Jun 3, 4:32 pm EDT | Joseph Edward TuckerChief Executive Officer, Director | 201,124 | — | — | 271,479 | — | |
| Jun 1, 2026 AForm 4 → | Jun 3, 4:30 pm EDT | Frank PasqualoneDirector | 18,518 | — | — | 26,423 | — | |
| Jun 1, 2026 AForm 4 → | Jun 3, 4:29 pm EDT | Michael D WebbDirector | 18,518 | — | — | 26,416 | — | |
| Jun 1, 2026 AForm 4 → | Jun 3, 4:27 pm EDT | Marcus SchabackerDirector | 18,518 | — | — | 26,418 | — | |
| Jun 1, 2026 AForm 4 → | Jun 3, 4:25 pm EDT | George A. KeglerDirector | 18,518 | — | — | 26,418 | — | |
| Jun 1, 2026 AForm 4 → | Jun 3, 4:23 pm EDT | Sheila DeWittDirector | 18,518 | — | — | 26,306 | — | |
| Jun 1, 2026 AForm 4 → | Jun 3, 4:22 pm EDT | Peter J. FacchiniChief Innovation Officer | 25,000 | — | — | 27,755 | — |
Reported at this company — derivatives (options, RSUs, warrants)
No reported derivative activity in this period.